We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-2.75%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.1B
AUM Growth
+$273M
(+2%)
Cap. Flow
-$650M
Cap. Flow
% of AUM
-4.61%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
703
New
–
Increased
221
Reduced
319
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$41.6M |
| 2 |
NVIDIA
NVDA
|
+$36M |
| 3 |
Intuitive Surgical
ISRG
|
+$33.8M |
| 4 |
Applied Materials
AMAT
|
+$32.4M |
| 5 |
XP
XP
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$57.8M |
| 2 |
Johnson & Johnson
JNJ
|
+$54.9M |
| 3 |
Danaher
DHR
|
+$41.9M |
| 4 |
Microsoft
MSFT
|
+$40.7M |
| 5 |
Lam Research
LRCX
|
+$37.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.08% |
| 2 | Technology | 25.64% |
| 3 | Financials | 11.81% |
| 4 | Industrials | 7.9% |
| 5 | Materials | 7.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Universal Display
OLED
$3.77B
| $29.7M | 0.21% |
189,172
-41,025
| -18% | -$6.23M |
|
102
Valero Energy
VLO
$90.5B
| $29.2M | 0.21% |
206,032
-71,601
| -26% | -$9.38M |
|
103
Texas Instruments
TXN
$252B
| $29.2M | 0.21% |
183,528
-40,930
| -18% | -$6.98M |
|
104
Fortive
FTV
$19.5B
| $28.8M | 0.2% |
515,224
+114,664
| +29% | +$6.59M |
|
105
Agilent Technologies
A
$39.9B
| $28.3M | 0.2% |
253,454
-245,402
| -49% | -$29.4M |
|
106
CrowdStrike
CRWD
$180B
| $27.9M | 0.2% |
667,408
-153,516
| -19% | -$5.97M |
|
107
Ecolab
ECL
$79.1B
| $27.7M | 0.2% |
163,652
+22,151
| +16% | +$4.03M |
|
108
AutoZone
AZO
$51.3B
| $26.7M | 0.19% |
10,497
-965
| -8% | -$2.42M |
|
109
Owens Corning
OC
$11.7B
| $26.6M | 0.19% |
194,673
-32,676
| -14% | -$4.49M |
|
110
Enphase Energy
ENPH
$4.7B
| $26.4M | 0.19% |
219,973
-57,807
| -21% | -$8.23M |
|
111
Bio-Rad Laboratories Class A
BIO
$8.82B
| $26.2M | 0.19% |
73,122
-18,869
| -21% | -$7.28M |
|
112
Becton Dickinson
BDX
$45.9B
| $26.1M | 0.19% |
101,068
-5,337
| -5% | -$1.44M |
|
113
Otis Worldwide
OTIS
$28.6B
| $25.8M | 0.18% |
321,708
-9,460
| -3% | -$809K |
|
|
BCYC
114
Bicycle Therapeutics
BCYC
$272M
| $25.2M | 0.18% |
1,253,261
-20,000
| -2% | -$457K |
|
115
Ionis Pharmaceuticals
IONS
$9.16B
| $24.9M | 0.18% |
549,067
+25,000
| +5% | +$1.03M |
|
116
NextEra Energy
NEE
$188B
| $24.8M | 0.18% |
432,511
-54,396
| -11% | -$3.77M |
|
117
Progressive
PGR
$128B
| $24.4M | 0.17% |
174,972
+455
| +0.3% | +$59.8K |
|
118
Bristol-Myers Squibb
BMY
$132B
| $23.9M | 0.17% |
412,307
-107,549
| -21% | -$6.59M |
|
119
Cintas
CTAS
$87.1B
| $23.6M | 0.17% |
196,560
-130,132
| -40% | -$16.2M |
|
120
Keros Therapeutics
KROS
$198M
| $23.6M | 0.17% |
741,061
+20,000
| +3% | +$747K |
|
121
SolarEdge
SEDG
$2.37B
| $23.6M | 0.17% |
182,246
+20,121
| +12% | +$3.86M |
|
122
Boston Scientific
BSX
$68.9B
| $23.5M | 0.17% |
444,231
+105,227
| +31% | +$5.52M |
|
123
Pfizer
PFE
$145B
| $23.3M | 0.17% |
701,789
+28,675
| +4% | +$1.01M |
|
124
Walt Disney
DIS
$170B
| $22.7M | 0.16% |
279,554
-142,633
| -34% | -$12.2M |
|
125
United Rentals
URI
$70.6B
| $22.7M | 0.16% |
50,953
-17,833
| -26% | -$8.16M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2023 Portfolio in Review
As of Q3 2023, Candriam SCA held 703 positions worth $14.1B, up 2% from $13.8B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Candriam SCA withdrew a net $650M in Q3 2023, closing 43 positions and reducing 319 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $31.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA added an estimated $41.6M to Amgen.
- Candriam SCA added most to Amgen in Q3 2023, an estimated $41.6M increase.
- Candriam SCA's biggest Q3 2023 reduction was Visa, cutting an estimated $57.8M.
- Candriam SCA fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $31.7M.
- Candriam SCA's ten largest holdings make up 33% of its $14.1B portfolio in Q3 2023.
- Candriam SCA opened 0 new positions and closed 43 in Q3 2023.
- Candriam SCA's portfolio value rose 2% quarter-over-quarter to $14.1B.
Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.